Biotech Values

[ghmm]

ADVM:

The primary reason to invest is not their cash (IMO). I am long (from higher prices unfortunately). They have a few interesting preclinical programs that should start entering the clinic later this year. If they really learned from the Avalanche failure then maybe their AMD program could be interesting too (but I don't put much value in it yet anyway).